Sign in
Active, not recruitingPhase 1

Intramyocardial Injection of Autologous UCB-MNC During Fontan Surgery for SRV Dependent CHD

Key facts

Who runs it
Timothy J Nelson, MD, PhD
Where
Aurora, Birmingham, Los Angeles, Oklahoma City, Philadelphia, and Rochester, United StatesSee the 6 sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
30 people enrolled
Started
1 Jun 2021
Ended
30 Aug 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Autologous mononuclear cells
Record updated
27 June 2025

Who can take part

Age
2 years to 5 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Diagnosis of a congenital hear defect with functionally single right ventricle (such as HLHS, HLHS variants, unbalanced AV septal defect with R dominance, DORV with Hypoplastic LV) undergoing Fontan surgical palliation
  • At least 2 and less than or equal to 5 years of age at time of Fontan surgical palliation
  • For subjects enrolling in the treatment arm, previous participation in clinical trial Umbilical Cord Blood Collection and Processing for Hypoplastic Left Heart Syndrome patients (NCT01856049) with autologous UCB-MNC product collected and available for distribution is required

Who cannot take part

  • Any of the following complications of his/her congenital heart disease:; any condition requiring urgent, or unplanned intervention procedure within 15 days prior to Fontan surgical palliation, unless complete and full cardiac recovery is documented by site investigator; severe pulmonary hypertension (reported in the medical record as >70% systemic pressure); Other clinical concerns as documented by a site investigator that would predict (more likely to happen than not to happen) a risk of severe complications or very poor outcome, not directly related tot he stem cell product or its injection procedure, during or after Fontan surgical palliation
  • Patient with prior surgical complications during the Fontan surgical palliation that resulted in or could be reasonably expected to significantly decrease cardiac function
  • History of DMSO reaction (treatment arm only subjects)
  • Severe chronic diseases at the discretion of the treating physician
  • Extensive extra-cardiac syndromic features
  • History of cancer
  • Individuals with severe heart failure that requires heart transplantation
  • Individuals with refractory or worsening arrhythmia
  • Parent(s) or legal guardian unwilling to have their child participate or unwilling to follow the study procedures
  • Individuals with an automated implantable cardioverter defibrillator (AICD) or pacemaker

Where in United States

  • Children's Hospital ColoradoAurora, United States
  • University of Alabama Medical CenterBirmingham, United States
  • Children's Hospital Los AngelesLos Angeles, United States
  • University of Oklahoma Medical CenterOklahoma City, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • Mayo ClinicRochester, United States

About the trial

What the trial wants to find out

Researchers want to better understand what happens to the heart when the autologous (from one's own body) stem cells are injected directly into muscle of the right side of the heart during the Fontan (Stage III) surgery. They want to see if there are changes in the electrical activity, the structure, and the function of the heart following this stem cell-based therapy. Researchers will compare the results from people who receive the stem cells to the results from people who do not receive the stem cells.

The 2 groups in the trial

  • Treatment ArmTreatment being tested

    Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 3 million cells per kilogram of body weight. This is a one time treatment at the time of Stage III Fontan surgery.

    Treatment: Autologous mononuclear cells

  • Control ArmNo study treatment, for comparison

    Control cohort not receiving the cell product, which will be enrolled and followed using the same inclusion/exclusion criteria and follow-up requirements as the treatment arm.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I Study of Intramyocardial Injection of Autologous Umbilical Cord Blood-Derived Mononuclear Cells During Fontan Surgical Palliation of Single Right Ventricle-Dependent Congenital Heart Disease
Record updated
27 June 2025